ESTRACISE protocol: 👉Effectiveness of transdermal estradiol in mitigating adverse effects of androgen deprivation 👉Synergistic benefits of transdermal estradiol & exercise in #ProstateCancer Heikki Seikkula Ilkka Jussila Teemu Murtola @eija_laakkonen Rob Newton doi.org/10.1111/bju.16…

Easier said than done, but physicians of patients with very advanced cancers should acknowledge when further treatment is futile and switch to palliative care. Giving oncological treatments until the last days does not give survival benefit, but can harm jamanetwork.com/journals/jamao…

Extraordinarily valuable data on 6 vs 24 mo ADT with salvage RT in RADICALS. Definitive MFS advantage at expense of added toxicity Like many trials, answers and creates many questions ⁦Chris Parker⁩ sciencedirect.com/science/articl…

Our Estonian-Finnish collaboration project on prognostic impact of positive surgical margins in #renalcancer surgery was awarded 3rd place award for best oncology posters in #eaubaltic2024 meeting. Congratulations Teesi Sepp!

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. #BeyondTheAbstract on UroToday > bit.ly/3x5kUHO Tapio Visakorpi Teemu Murtola Naser Ansari-Pour

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. #BeyondTheAbstract on UroToday > bit.ly/3x5kUHO Tapio Visakorpi Teemu Murtola Naser Ansari-Pour

We are happy to report that #ESTO2, our first-ever phase 3 RCT on efficacy of atorvastatin in combination with ADT against advanced #prostatecancer has now recruited over 200 patients, surpassing 50% of the recruitment target. Recruitment speed currently approx 7 patients/month

This very interesting study raises a clinically relevant question: does PSMA-PET at PSA relapse of localized #prostatecancer detect metastases earlier, or rather only more indolent disease? This study suggests the latter, more benign pheno/fenotype and survival after PSMA-detect.

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. #BeyondTheAbstract on UroToday > bit.ly/3x5kUHO Tapio Visakorpi Teemu Murtola Naser Ansari-Pour

Dr. Roni Joentausta defended succesfully his PhD thesis on statins, metformin and prostate cancer survival and risk of erectile dysfunction after radical prostatectomy. Opponent was professor Timo Strandberg, Teemu Murtola served as kustos. Congratulations to Roni!

Great slide from Christopher Sweeney, MBBS #ESMO24 highlighting a model of personalising prostate cancer care in 2024!

A report from Advenced prostate cancer consensus conference #APCCC24 now out in European Urology 👍 sciencedirect.com/science/articl…

Annual retreat of the Tampere Prostate Cancer Research Center: Excellent talks in pleasant surroundings with brilliant people. Next up: sauna with a dip in the not quite yet frozen lake Näsijärvi Thanks to everyone attending!

Utmost BS. Those "hidden issues" will lead to overtreatment and just psychological distress effectively reversing the "longevity". Just BS. Eat healthy. Exercise. Enjoy life. And for genetics you can't do anything. That longevity. Not MRIs.

Toivoisin, että terveydenhuollossa pysyttäisiin näyttöön perustuvissa hoidoissa. Yksityisen terv.huollon uskottavuus ei tällaisesta parane. #mehiläinen #eiransairaala Uskomushoidoista Huuhaa-palkinto Eiran sairaalalle ja Mehiläiselle laakarilehti.fi/terveydenhuolt…

PCa: Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer by Teemu Murtola et al Full article: buff.ly/4gfHWft #UroSoMe #MedTwitter #euros #PCa #ProstateCancer